Pharmacokinetics, brain distribution, and plasma protein binding of the antiepileptic drug lacosamide in rats

Archives of Pharmacal Research

Volumn 34, Issue 12, 2011, Pages 2059-2064

  Koo, Tae Sung ^a   Kim, Soo Jin ^a   Ha, Dong Jin ^a   Baek, Myoungki ^a   Moon, Hongsik ^a  

^a SK Holdings Co Ltd   (South Korea)

Author keywords

Bioavailability; Brain Distribution; Lacosamide; Pharmacokinetics; Plasma protein binding

Indexed keywords

HARKOSERIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG PROTEIN BINDING; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACETAMIDES; ANIMALS; ANTICONVULSANTS; BLOOD PROTEINS; BRAIN; MALE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84863120232     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-011-1208-7     Document Type: Article

References (15)

1. Beydoun, D'Souza, J., Hebert, D., and Doty, P., Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev. Neurother., 9, 33-42 (2009).
2. Beyreuther, B. K., Freitag, J., Heers, C., Krebsfänger, N., Scharfenecker, U., and Stöhr, T., Lacosamide: a review of preclinical properties. CNS Drug Rev., 13, 21-42 (2007). (Pubitemid 46697839)
3. Blume, W. T., Lüders, H. O., Mizrahi, E., Tassinari, C., van Emde Boas, W., and Engel, J., Jr., Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology. Epilepsia, 42, 1212-1218 (2001). (Pubitemid 32951809)
4. Cross, S. A. and Curran, M. P., Lacosamide: in partial onset seizures. Drugs, 69, 449-459 (2009).
5. Davies, B. and Morris, T., Physiological parameters in laboratory animals and humans. Pharm. Res., 10, 1093-1095 (1993). (Pubitemid 23211439)
6. Doty, P., Rudd, G., Stoehr, T., and Thomas, D., Lacosamide. Neurotherapeutics, 4, 145-148 (2007). (Pubitemid 46107317)
7. Errington, A. C., Coyne, L., Stöhr, T., Selve, N., and Lees, G., Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology, 50, 1016-1029 (2006). (Pubitemid 43794912)
8. Errington, A. C., Stöhr, T., Heers, C., and Lees, G., The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol., 73, 157-169 (2008). (Pubitemid 350294207)
9. Halász, P., Kälviäinen, R., Mazurkiewicz- Beldziñska, M., Rosenow, F., Doty, P., Hebert, D., and Sullivan, T., SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia, 50, 443-453 (2009).
10. Horstmann, R., Bonn, R., Cawello, W., Doty, P., and Rudd, D., Basic clinical pharmacological investigations of the new antiepileptic drug SPM 927. Epilepsia, 43 Suppl 7, Abst 188 (2002).
11. Hovinga, C. A., SPM-927 (Schwarz Pharma). IDrugs, 6, 479-485 (2003).
12. Kim, S. J., Koo, T. S., Ha, D. J., Baek, M., Lee, S. K., Shin, D. S., and Moon, H., Liquid chromatography-tandem mass spectrometry for quantification of lacosamide, an antiepileptic drug, in rat plasma and its application to pharmacokinetic study. Biomed. Chromatogr., DOI 10.1002/bmc. 1668 (2011).
13. Kropeit, D., Schiltmeyer, B., Cawello, W., Hammes, W., and Horstmann, R., Bioequivalence of short-time infusions compared to oral administration of SPM 927. Epilepsia, 45 Suppl 7, Abst 1.323 (2004).
14. Kropeit, D., Koch, B., Schilmeyer, B., Cawello, W., Horstmann, R., and Scharfenecker, U., Low drug-interaction potential of lacosamide. J. Pain, 6 Suppl 1, Abst S34 (2005).
15. Schmidt, D., The clinical impact of new anti-epileptic drugs after a decade of use in epilepsy. Epilepsy Res., 50, 21-32 (2002). (Pubitemid 34876583)